S‑23

S-23 operates as a selective partial agonist of the androgen receptor. Unlike full agonists that maximally activate the receptor, S-23 binds with high affinity but only partially activates the receptor’s transcriptional activity. This unique pharmacological profile allows it to stimulate muscle protein synthesis and inhibit muscle protein breakdown while potentially reducing the activation of androgenic pathways in non-muscle tissues. Research suggests this selectivity may contribute to a more favorable side-effect profile compared to non-selective SARMs or anabolic steroids. The compound is orally active and does not require esterification for storage, leading to a shorter half-life and more rapid clearance. This mechanism is central to its reputation in research settings for promoting lean mass gains with minimal impact on lipid profiles or blood pressure, although individual responses vary based on dosage and cycle length.

In research and athletic contexts, S-23 is predominantly utilized for cutting and recomposition cycles. Its primary application is maintaining or building lean muscle mass while in a caloric deficit, a challenge where traditional training often leads to muscle catabolism. Users report that S-23 helps preserve strength levels during dieting phases, allowing for continued high-intensity training without significant performance drops. It is less commonly used for pure bulking cycles due to its moderate anabolic potency compared to stronger SARMs like LGD-4033. However, it is frequently stacked with other compounds to enhance fat loss while mitigating muscle loss. The compound is also studied for its potential to improve body composition in older adults or those with sarcopenia, though this is largely theoretical in the current market. Its ability to provide a 'dry' look without water retention makes it a popular choice for pre-competition preparation in research settings.

Standard research protocols for S-23 typically range from 10 mg to 30 mg per day. Most users start at the lower end to assess tolerance before increasing the dose. A common intermediate protocol involves 15 mg per day for 8 to 12 weeks. Advanced users may push doses up to 30 mg, but this is rarely necessary for most research goals and may increase the risk of side effects. Cycle lengths generally span 8 to 12 weeks, as the compound is not typically used for longer durations due to the potential for androgenic suppression. It is crucial to note that S-23 is often taken in the morning due to its half-life. Stacking is common, with researchers pairing it with other SARMs to maximize efficacy. Always start with the lowest effective dose to minimize potential adverse reactions and monitor blood work regularly during the cycle.

While S-23 is considered to have a milder profile than many other SARMs, it is not without potential side effects. Users may report mild suppression of natural testosterone production, which can lead to low energy, mood changes, or libido issues if not managed. Post-cycle therapy (PCT) is generally recommended after cycles longer than 4 weeks to restore natural hormone production. Other reported side effects include mild headaches, nausea, or changes in sleep patterns. Because S-23 is a partial agonist, the risk of severe androgenic side effects like acne or hair loss is lower than with full agonists, but it is not zero. Regular blood work is essential to monitor liver enzymes, lipid profiles, and hormone levels. Individuals with pre-existing health conditions should consult a healthcare professional before using any research compound. Safety should always be the primary concern in any research protocol.

Mechanism of action

S-23 acts as a selective partial agonist of the androgen receptor, stimulating muscle protein synthesis while potentially reducing androgenic side effects through its unique binding affinity.